Trimelamol | CAS#64124-21-6 | biochemical

MedKoo Cat#: 146035 | Name: Trimelamol

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Trimelamol is a synthetic drug primarily used for its anti-inflammatory and immunosuppressive effects. It works by inhibiting the activity of certain enzymes and pathways involved in the inflammatory response, such as the cyclooxygenase (COX) pathway, which reduces the production of pro-inflammatory prostaglandins. Trimelamol is typically used to manage conditions like rheumatoid arthritis and other autoimmune disorders by suppressing excessive immune system activity. Its effectiveness in controlling inflammation makes it useful in both acute and chronic inflammatory conditions.

Chemical Structure

Trimelamol

CAS#64124-21-6

Theoretical Analysis

MedKoo Cat#: 146035

Name: Trimelamol

CAS#: 64124-21-6

Chemical Formula: C9H18N6O3

Exact Mass: 258.1400

Molecular Weight: 258.28

Elemental Analysis: C, 41.85; H, 7.02; N, 32.54; O, 18.58

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Trimelamol;

IUPAC/Chemical Name

((1,3,5-triazine-2,4,6-triyl)tris(methylazanediyl))trimethanol

InChi Key

MHVFYGIQJNFWGQ-UHFFFAOYSA-N

InChi Code

1S/C9H18N6O3/c1-13(4-16)7-10-8(14(2)5-17)12-9(11-7)15(3)6-18/h16-18H,4-6H2,1-3H3

SMILES Code

CN(CO)C1=NC(=NC(=N1)N(C)CO)N(C)CO

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 258.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Jackson C, Crabb TA, Gibson M, Godfrey R, Saunders R, Thurston DE. Studies on the stability of trimelamol, a carbinolamine-containing antitumor drug. J Pharm Sci. 1991 Mar;80(3):245-51. doi: 10.1002/jps.2600800311. PMID: 2051341. 2: Gibson M, Denham AJ, Taylor PM, Payne NI. Development of a parenteral formulation of trimelamol, a synthetic S-triazine carbinolamine-containing cytotoxic agent. J Parenter Sci Technol. 1990 Nov-Dec;44(6):306-13. PMID: 2277318. 3: Judson IR, Rutty CJ, Abel G, Graham MA. Low central nervous system penetration of N2,N4,N6,-trihydroxymethyl-N2,N4,N6,-trimethylmelamine (Trimelamol): a cytotoxic s-triazine with reduced neurotoxicity. Br J Cancer. 1986 May;53(5):601-6. doi: 10.1038/bjc.1986.102. PMID: 3087399; PMCID: PMC2001385. 4: Rutty CJ, Judson IR, Abel G, Goddard PM, Newell DR, Harrap KR. Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water- soluble cytotoxic s-triazine which does not require metabolic activation. Cancer Chemother Pharmacol. 1986;17(3):251-8. doi: 10.1007/BF00256694. PMID: 3091280. 5: Jackson C, Hartley JA, Jenkins TC, Godfrey R, Saunders R, Thurston DE. N2,N4,N6-tri(hydroxymethyl)-N2,N4,N6-trimethylmelamine (trimelamol) is an efficient DNA cross-linking agent in vitro. Biochem Pharmacol. 1991 Nov 6;42(11):2091-7. doi: 10.1016/0006-2952(91)90343-4. PMID: 1958227. 6: Ramurthy S, Miller MJ. Framework-Reactive Siderophore Analogs as Potential Cell-Selective Drugs. Design and Syntheses of Trimelamol-Based Iron Chelators. J Org Chem. 1996 Jun 14;61(12):4120-4124. doi: 10.1021/jo9600621. PMID: 11667292. 7: Coley HM, Brooks N, Phillips DH, Hewer A, Jenkins TC, Jarman M, Judson IR. The role of the N-(hydroxymethyl)melamines as antitumour agents: mechanism of action studies. Biochem Pharmacol. 1995 May 11;49(9):1203-12. doi: 10.1016/0006-2952(95)00040-7. PMID: 7763301. 8: Coley HM, Jarman M, Brooks N, Thornton TJ, Judson IR. Stable analogues of the antitumour agent trimelamol retain in vitro cytotoxicity in drug-sensitive and resistant rodent and human cell lines. Eur J Cancer. 1994;30A(12):1827-36. doi: 10.1016/0959-8049(94)00323-w. PMID: 7880614. 9: Yamada Y, Kubota T, Hoshiya Y, Asanuma F, Koh J, Kitajima M, Coley H, Judson I. Antitumor effect of trimelamol against human breast carcinoma xenografts in nude mice. Oncol Rep. 1996 Jul;3(4):613-7. doi: 10.3892/or.3.4.613. PMID: 21594422. 10: Judson IR, Calvert AH, Rutty CJ, Abel G, Gumbrell LA, Graham MA, Evans BD, Wilman DE, Ashley SE, Cairnduff F. Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine). Cancer Res. 1989 Oct 1;49(19):5475-9. PMID: 2670205. 11: Coley HM, Jarman M, Brooks N, Kubota T, Goddard PM, Jones M, Lee N, Owens MD, Halbert GW, Judson IR. Pre-clinical development of the anti-tumour agent CB 7646, bis N-(hydroxymethyl) trimethylmelamine, a stable analogue of trimelamol. Int J Cancer. 1996 Nov 4;68(3):356-63. doi: 10.1002/(SICI)1097-0215(19961104)68:3<356::AID-IJC14>3.0.CO;2-6. PMID: 8903478. 12: Jarman M, Coley HM, Judson IR, Thornton TJ, Wilman DE, Abel G, Rutty CJ. Synthesis and cytotoxicity of potential tumor-inhibitory analogues of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron- withdrawing groups in place of methyl. J Med Chem. 1993 Dec 24;36(26):4195-200. doi: 10.1021/jm00078a008. PMID: 8277501. 13: Coley HM. N-(Hydroxymethyl) melamines. Gen Pharmacol. 1997 Feb;28(2):177-82. doi: 10.1016/s0306-3623(96)00172-3. PMID: 9013191. 14: Judson IR, Calvert AH, Gore ME, Balmanno K, Gumbrell LA, Perren T, Wiltshaw E. Phase II trial of trimelamol in refractory ovarian cancer. Br J Cancer. 1991 Feb;63(2):311-3. doi: 10.1038/bjc.1991.72. PMID: 1997112; PMCID: PMC1971798. 15: Boven E, Nauta MM, Schlüper HM, Erkelens CA, Pinedo HM. Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts. Cancer Chemother Pharmacol. 1986;18(2):124-8. doi: 10.1007/BF00262280. PMID: 3098444. 16: Bermudez J, Boyle EA, Miner WD, Sanger GJ. The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. Br J Cancer. 1988 Nov;58(5):644-50. doi: 10.1038/bjc.1988.277. PMID: 2851311; PMCID: PMC2246836. 17: Beijnen JH, Flora KP, Halbert GW, Henrar RE, Slack JA. CRC/EORTC/NCI Joint Formulation Working Party: experiences in the formulation of investigational cytotoxic drugs. Br J Cancer. 1995 Jul;72(1):210-8. doi: 10.1038/bjc.1995.305. PMID: 7599054; PMCID: PMC2034157. 18: Sampedro F, Partika J, Santalo P, Molins-Pujol AM, Bonal J, Perez-Soler R. Liposomes as carriers of different new lipophilic antitumour drugs: a preliminary report. J Microencapsul. 1994 May-Jun;11(3):309-18. doi: 10.3109/02652049409040460. PMID: 8064554. 19: Coley HM, Jarman M, Jones M, Sargent JM, Kubota T, Lee NC, Goddard PM, Elgie AW, Williamson C, Taylor CG, Judson IR. The activity of N-(hydroxymethyl) melamines in fresh human ovarian tumour cells and xenografts. Anticancer Res. 1996 Jul-Aug;16(4A):1851-5. PMID: 8712712. 20: Efimov VA, Fediunin SV, Chakhmakhcheva OG. [Application of BODIPY- trimethylmelamine conjugate for DNA cross-linking in vitro]. Bioorg Khim. 2011 Mar-Apr;37(2):278-83. Russian. PMID: 21721261.